Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
about
Dynamic effects of antibody-dependent enhancement on the fitness of virusesSensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.Challenges and opportunities for development of an AIDS vaccine.Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexesCausal Vaccine Effects on Binary Postinfection Outcomes.Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission.Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.Monoclonal antibodies for reproductive health: Part I. Preventing sexual transmission of disease and pregnancy with topically applied antibodies.Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxiHIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.Chop-lump tests for vaccine trials.Evaluating the efficacy of a malaria vaccine.Some statistical issues in HIV vaccine trials.
P2860
Q27472667-1791AB25-3D88-4D06-BF22-C27A1A429091Q30336405-93F17ECF-3A5B-450D-97AA-5A1A43554FC8Q33942996-BFE97C8B-74D3-4123-A7A6-2DE7AAB18953Q34671059-25302639-5303-4B31-9062-F4C16565EE1AQ37016771-FF67DA81-9C6C-43B4-BA4F-DD05483C4A0FQ37360764-2A705D0C-2624-4A9E-B694-63A71DDEBAF1Q40565010-39BC0D70-2407-4EFD-BBD9-EFBED1F49C52Q40573271-0C73CC0D-3FA1-4777-A444-B3D67DCDB22BQ40601784-E8A47958-2F48-4BDE-BED7-9FDD509BF3DDQ40640688-B099DF91-AD84-49F8-AAD3-B1DC1BBB3BBEQ47894801-1238BBF5-3343-4B35-AE75-EB98269A480DQ51703370-594A46CB-C4AF-43DC-ACE1-CE1BB938F174Q52846439-F168FC6B-24D7-41A9-B9A2-C62835162378
P2860
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
@ast
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
@en
type
label
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
@ast
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
@en
prefLabel
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
@ast
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
@en
P356
P1476
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
@en
P2093
P304
P356
10.1353/PBM.1992.0048
P577
1992-01-01T00:00:00Z